ResMed
Bella Vista (Deerubbin), New South Wales.
Lasting legacy and recognition
Recognition at the awards validates the ResMed team’s hard work and dedication. It not only enhances ResMed’s reputation, but also highlights the leadership and innovative strategies that have driven the company’s success.
Brendan Mullins, ResMed VP Global Manufacturing & Engineering.
International Health winner - ResMed.
ResMed breathes new life into Aussie healthcare exports
21 November 2024
ResMed’s 35-year legacy of innovation continues with cutting-edge digital health solutions that improve quality of life.
Operating in more than 140 countries, ResMed has revolutionised respiratory care and sleep therapy. Its vision is to positively impact 250 million lives by 2025. The company is doing this through advanced manufacturing, smart user-centric design, and cutting-edge technology.
‘Our goal is to lead positive change in the healthcare industry, ensuring high-quality care for all,’ says Brendan Mullins, ResMed VP Global Manufacturing & Engineering. ResMed is the winner of the 2024 International Health award category at the 62nd Australian Export Awards.
Better solutions for a global chronic health issue
In 1989, ResMed founder Peter Farrell envisioned better solutions for patients needing continuous positive airway pressure (CPAP) therapy.
CPAP therapy uses devices to deliver constant and steady air pressure to the lungs, helping people breathe. It’s a common therapy for obstructive sleep apnoea, a condition affecting an estimated 936 million people globally. It is also used in Chronic Obstructive Pulmonary Disease (COPD), which affects a further 380 million people.
Since its beginnings, ResMed has delivered on Farrell’s vision. It designs and makes CPAP masks, CPAP machines and in-home life support ventilators more comfortable, quieter and easier to use.
Responding to a global demand for personalised healthcare
ResMed’s comprehensive software platforms further support personalised care plans, giving people back their autonomy and keeping them out of hospital. These digital solutions respond to a global demand for more personalised care. ‘People want access to their data, and they want it kept private, secure and sharable, with their consent, with health providers,’ says Mullins.
ResMed’s cloud health management system has almost 7 million patients and more than 16 billion points of medical data. This makes it one of the world’s largest outside-hospital care networks.
‘We have the opportunity to not just tap into this market trend, but to lead the entire market,’ says Mullins.
A perfect storm successfully weathered
Last year, global supply chain challenges and other issues created a perfect storm of increased demand and reduced supply. Faced with a limited number of semiconductor chips used in its devices, ResMed quickly pivoted to provide its flagship device with a Card-to-Cloud (C2C) feature. This removed the need for the impacted chips and created a new pathway for uploading data to ResMed’s cloud-based platform.
‘We were able to pivot our strategy, redesign, reengineer and manufacture another sleep apnea device to meet acute market needs,’ says Mullins. ‘This showcases the purpose of every talented ResMedian in focusing on the person who needs our products.’
Reaching 800,000 patients worldwide
Weathering the perfect storm, the ResMed team achieved a significant milestone in FY2024. It released its products to more than 800,000 patients worldwide. The company also saw 30% growth in the US, Canada and Latin America. ‘As a wider business, we’re so proud of our double-digit year-on-year growth,’ says Mullins.
We are empowering healthcare providers with cutting-edge cloud applications for patient monitoring and support.
Brendan Mullins, ResMed VP Global Manufacturing & Engineering.
Global R&D builds innovative, relevant products
ResMed conducts R&D across the world, in Dublin, Singapore, Los Angeles and at its Sydney HQ.
‘Our Sydney campus is unique across our global sites as it integrates both our innovation and manufacturing teams,’ says Mullins. ‘This enables seamless product development from concept to production.’
In 2023, ResMed allocated 7-8% of its net revenues to R&D. ‘This investment fuels our continuous pursuit of excellence, driving innovation in therapy experiences,’ says Mullins. ‘We are empowering healthcare providers with cutting-edge cloud applications for patient monitoring and support.’
A lasting legacy of recognition
ResMed’s recognition as the winner of the International Health award category is just the latest in the company’s long history at the Australian Export Awards. The company was the Australian Exporter of the Year in 2006 and 2002. It was also the winner of the Large Advanced Manufacturer award category in these years.
It was also a finalist in the Large Advanced Manufacturer category in 2010, 2009, 2005, 2004, 1998 and 1995. It was recognised in the Emerging Exporter category in 1991 and 1992. 'Recognition at the awards validates the ResMed team’s hard work and dedication', says Mullins. ‘It not only enhances ResMed’s reputation, but also highlights the leadership and innovative strategies that have driven the company’s success.’
Life-changing sleep therapy to millions more
Looking ahead, ResMed remains dedicated to advancing global health through innovative solutions and adaptable strategies.
ResMed's next target markets include regions across Asia and India. It is targeting these regions due to their growing populations, increasing prevalence of chronic diseases, and rising demand for healthcare solutions.
‘We will continue to innovate to set new standards of product performance and patient care,’ says Mullins. ‘Ultimately, we want to bring life-changing sleep therapy to millions more patients each year.’
Visit ResMed website.
